Loading...
Thumbnail Image
Publication

ADAM-1: An AI Reasoning and Bioinformatics Model for Alzheimer's Disease Detection and Microbiome-Clinical Data Integration

Huang, Ziyuan
Kaur Sekhon, Vishaldeep
Sadeghian, Roozbeh
Vaida, Maria L
Jo, Cynthia
McCormick, Beth A
Ward, Doyle V
Bucci, Vanni
Haran, John P
Embargo Expiration Date
Abstract

Alzheimer's Disease Analysis Model Generation 1 (ADAM-1) is a multi-agent reasoning large language model (LLM) framework designed to integrate and analyze multimodal data, including microbiome profiles, clinical datasets, and external knowledge bases, to enhance the understanding and classification of Alzheimer's disease (AD). By leveraging the agentic system with LLM, ADAM-1 produces insights from diverse data sources and contextualizes the findings with literature-driven evidence. A comparative evaluation with XGBoost revealed a significantly improved mean F1 score and significantly reduced variance for ADAM-1, highlighting its robustness and consistency, particularly when utilizing human biological data. Although currently tailored for binary classification tasks with two data modalities, future iterations will aim to incorporate additional data types, such as neuroimaging and peripheral biomarkers, and expand them to predict disease progression, thereby broadening ADAM-1's scalability and applicability in AD research and diagnostic applications.

Source

Huang Z, Kaur Sekhon V, Sadeghian R, Vaida ML, Jo C, McCormick BA, Ward DV, Bucci V, Haran JP. ADAM-1: An AI Reasoning and Bioinformatics Model for Alzheimer's Disease Detection and Microbiome-Clinical Data Integration. IEEE Access. 2025;13:145953-145967. doi: 10.1109/access.2025.3599857. Epub 2025 Aug 18. PMID: 41036149; PMCID: PMC12483529.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1109/access.2025.3599857
PubMed ID
41036149
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright 2025 The Authors. This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see https://creativecommons.org/licenses/by/4.0/